Pelthos Therapeutics Inc（PTHS）資訊與事件PTHSPelthos Therapeutics Inc

Pelthos Therapeutics Inc Trading Halted Due to Volatility Trading Pause

Pelthos Therapeutics Inc trading halted, volatility trading pause

Pelthos Reports Q1 Revenue of $10.91M, Exceeding Expectations

Reports Q1 revenue $10.91M, consensus $10.44M. Scott Plesha, CEO of Pelthos, stated, "In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of our sales force and focused commercial execution. The increase in dispensed units positions us well for continued growth in the second quarter and beyond. Looking ahead, we anticipate ongoing growth for ZELSUVMI, with dispensed units in April reaching 3,776 and total units dispensed since launch surpassing a significant milestone of 20,000. We believe our continued commercial performance, paired with the Horizon facility we entered into earlier this year, will provide us the capital and flexibility needed to advance our business plan, including the planned commercialization of XEPI and XEGLYZE in early 2027 and mid-2027, respectively."

Pelthos Therapeutics Appoints John Gay as CFO

Pelthos Therapeutics announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos' CFO since July 2025. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience.